ReviewInternational journal of molecular sciences2018
Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis.FEBS open bio · 2019Pooled it
- Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application.Journal of surgical oncology · 2026Review
- Pazopanib in patients with primary multi-metastatic bone Ewing sarcoma.Frontiers in oncology · 2025Article
- Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: a case report and review of the literature.Frontiers in oncology · 2025Article
- Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.Mini reviews in medicinal chemistry · 2024Review
- Outcome of patients with soft tissue sarcomas of the extremities and trunk treated by (neo)adjuvant intensity modulated radiation therapy with curative intent.Radiation oncology (London, England) · 2023Article
- Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.Cell death & disease · 2023Article
- Alveolar soft part sarcoma: progress toward improvement in survival? A population-based study.BMC cancer · 2022Article
- Tyrosine kinase inhibitors in sarcoma treatment.Oncology letters · 2022Review
- New adjustable modular hemipelvic prosthesis replacement with 3D-print osteotomy guide plate used in periacetabular malignant tumors: a retrospective case series.Journal of orthopaedic surgery and research · 2022Article
- Article
- Nanomaterial Technology and Soft Tissue Sarcomas.Frontiers in oncology · 2022Review
- Desmoplastic Small Round Cell Tumor in a Pregnant Woman: A Case Report and Literature Review.The Yale journal of biology and medicine · 2021Review
- Liquid Biopsy: A New Translational Diagnostic and Monitoring Tool for Musculoskeletal Tumors.International journal of molecular sciences · 2021Review
- Review
- Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.Frontiers in oncology · 2021Review
- Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation.JCO precision oncology · 2021Article
- Bone and Soft Tissue Sarcoma.Cancers · 2020Article
- Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries.World journal of clinical cases · 2020Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bone and soft tissue sarcoma. As one of the first molecular targeted drugs approved for solid malignant tumors, imatinib's approval as a treatment for gastrointestinal stromal tumors (GISTs) has been a great achievement. Following imatinib, other tyrosine kinase inhibitors (TKIs) have been approved for GISTs such as sunitinib and regorafenib, and pazopanib was approved for non-GIST soft tissue sarcomas. Olaratumab, the monoclonal antibody that targets platelet-derived growth factor receptor (PDGFR)-α, was shown to extend the overall survival of soft tissue sarcoma patients and was approved in 2016 in the U.S. as a breakthrough therapy. For bone tumors, new drugs are limited to denosumab, a receptor activator of nuclear factor κB ligand (RANKL) inhibitor, for treating giant cell tumors of bone. In this review, we explain and summarize the current molecular targeting therapies approved and in development for bone and soft tissue sarcomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.